Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae
Authors:
Open Access
- 16 January 2024
- journal article
- research article
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 37 (2) , 158-162
Abstract
Objectives. We assessed the in vitro activity of delafloxacin and the synergy between cefotaxime and delafloxacin among cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae (CNSSP). Material and methods. A total of 30 CNSSP (cefotaxime MIC > 0.5 mg/L) were studied. Serotyping was performed by the Pneumotest-Latex and Quellung reaction. Minimum inhibitory concentrations (MICs) of delafloxacin, levofloxacin, penicillin, cefotaxime, erythromycin and vancomycin were determined by gradient diffusion strips (GDS). Synergistic activity of delafloxacin plus cefotaxime against clinical S. pneumoniae isolates was evaluated by the GDS cross method. Results. Delafloxacin showed a higher pneumococcal activity than its comparator levofloxacin (MIC50, 0.004 versus 0.75 mg/L and MIC90, 0.047 versus >32 mg/L). Resistance to delafloxacin was identified in 7/30 (23.3%) isolates, belonging to serotypes 14 and 9V. Synergy between delafloxacin and cefotaxime was detected in 2 strains (serotypes 19A and 9V). Antagonism was not observed. Addition of delafloxacin increased the activity of cefotaxime in all isolates. Delafloxacin susceptibility was restored in 5/7 (71.4%) strains. Conclusions. CNSSP showed a susceptibility to delafloxacin of 76.7%. Synergistic interactions between delafloxacin and cefotaxime were observed in vitro among CNSSP by GDS cross method.Keywords
This publication has 16 references indexed in Scilit:
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Emerging concepts in the pathogenesis of theStreptococcus pneumoniae: From nasopharyngeal colonizer to intracellular pathogenCellular Microbiology, 2019
- Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic PropertiesInfectious Diseases and Therapy, 2018
- In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014Antimicrobial Agents and Chemotherapy, 2017
- In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisAntimicrobial Agents and Chemotherapy, 2016
- In vitro synergy of penicillin, ceftriaxone and levofloxacin against serotype 19A Streptococcus pneumoniaeInternational Journal of Antimicrobial Agents, 2015
- Comparative evaluation of synergy of combinations of -lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2011
- Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococciJournal of Antimicrobial Chemotherapy, 2004
- Meropenem Prevents Levofloxacin-Induced Resistance in Penicillin-Resistant Pneumococci and Acts Synergistically with Levofloxacin in Experimental MeningitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E testAntimicrobial Agents and Chemotherapy, 1996